Linked e-resources
Details
Table of Contents
Intro; Preface; Contents; 1: Taxonomy of Medication Adherence: Recent Developments; 1.1 Introduction; 1.2 Terminology: The Difficulty of Choosing the Right Term!; 1.3 The New European Consensus-Based terminology; 1.4 Terminologies Associated with the Quantification of Adherence to Medications; References; Part I: Measuring Drug Adherence; 2: Qualitative Assessments of Adherence; 2.1 Introduction; 2.2 What Are the Characteristics of a Valid and Useful Method to Assess Adherence to the Medication?; 2.3 The Patient Interviews by Physicians or Third Parties and Patient's Diaries.
2.4 Use of Questionnaires in HypertensionReferences; 3: Electronic Monitoring of Medication Adherence: From Dose-Counting to Dose-Clocking; 3.1 History of MEMS Monitoring and Bibliometry; 3.2 Indirect Versus Direct Measure; 3.3 From Reliable Measure to Effective Interventions; 3.4 "Real-Time": What Does It Mean?; References; 4: Measurements of Antihypertensive Medications in Blood and Urine; 4.1 Background; 4.2 Principle of LC-MS/MS; 4.2.1 Sample Derivatisation; 4.2.2 High Performance Liquid Chromatography (HPLC); 4.2.3 Mass Spectrometry (Fig. 4.2).
4.3 The Biochemical Principles of Assessment of Non-Ưadherence to Antihypertensive Treatment4.4 Laboratory Processing of Samples; 4.5 Detecting Non-adherence to Antihypertensive Treatment; 4.6 Prevalence and Risk Factors of Non-adherence to Antihypertensive Medications: Insights from Biochemical Analysis of Bodily Fluids by HPLC-MS/MS; 4.7 Our Clinical Experience; 4.8 Other Benefits of Biochemical Testing for Non-Ưadherence to Antihypertensive Treatment; 4.9 The Future; References.
5: Adherence to Antihypertensive and Cardiovascular Preventive Treatment: The Contribution of the Lombardy Database5.1 Adherence to Drug Treatment in Hypertension; 5.2 Adherence and Type of Initial Antihypertensive Monotherapy; 5.3 Factors Involved in Adherence to Antihypertensive Drugs; 5.4 Adherence to Treatment and Cardiovascular Risk; 5.5 Combination Treatment; 5.6 Adherence and Other Cardiovascular Drugs; References; 6: Directly Observed Therapy in Hypertension (DOT-HTN); 6.1 Background and Rationale; 6.1.1 Historical Background of Directly Observed Therapy (DO T).
6.1.2 DOT in Hypertension6.1.2.1 Safety of DOT in Hypertension; 6.2 Methods; 6.2.1 Research Questions; 6.2.2 Review Methodologies and Literature Search; 6.2.3 Selection Criteria; 6.2.4 Search in International Trials Registries; 6.2.5 Data Extraction from Published Research; 6.3 Results; 6.3.1 Identified Ongoing Trials; 6.3.2 Identified Published Research; 6.3.3 DOT-HTN Procedures Reported in the Reviewed Literature; 6.4 Discussion; References; 7: Digital Medicines to Measure Drug Ingestion Adherence; 7.1 Introduction; 7.2 Digital Medicines; 7.3 Pre-approval Studies.
2.4 Use of Questionnaires in HypertensionReferences; 3: Electronic Monitoring of Medication Adherence: From Dose-Counting to Dose-Clocking; 3.1 History of MEMS Monitoring and Bibliometry; 3.2 Indirect Versus Direct Measure; 3.3 From Reliable Measure to Effective Interventions; 3.4 "Real-Time": What Does It Mean?; References; 4: Measurements of Antihypertensive Medications in Blood and Urine; 4.1 Background; 4.2 Principle of LC-MS/MS; 4.2.1 Sample Derivatisation; 4.2.2 High Performance Liquid Chromatography (HPLC); 4.2.3 Mass Spectrometry (Fig. 4.2).
4.3 The Biochemical Principles of Assessment of Non-Ưadherence to Antihypertensive Treatment4.4 Laboratory Processing of Samples; 4.5 Detecting Non-adherence to Antihypertensive Treatment; 4.6 Prevalence and Risk Factors of Non-adherence to Antihypertensive Medications: Insights from Biochemical Analysis of Bodily Fluids by HPLC-MS/MS; 4.7 Our Clinical Experience; 4.8 Other Benefits of Biochemical Testing for Non-Ưadherence to Antihypertensive Treatment; 4.9 The Future; References.
5: Adherence to Antihypertensive and Cardiovascular Preventive Treatment: The Contribution of the Lombardy Database5.1 Adherence to Drug Treatment in Hypertension; 5.2 Adherence and Type of Initial Antihypertensive Monotherapy; 5.3 Factors Involved in Adherence to Antihypertensive Drugs; 5.4 Adherence to Treatment and Cardiovascular Risk; 5.5 Combination Treatment; 5.6 Adherence and Other Cardiovascular Drugs; References; 6: Directly Observed Therapy in Hypertension (DOT-HTN); 6.1 Background and Rationale; 6.1.1 Historical Background of Directly Observed Therapy (DO T).
6.1.2 DOT in Hypertension6.1.2.1 Safety of DOT in Hypertension; 6.2 Methods; 6.2.1 Research Questions; 6.2.2 Review Methodologies and Literature Search; 6.2.3 Selection Criteria; 6.2.4 Search in International Trials Registries; 6.2.5 Data Extraction from Published Research; 6.3 Results; 6.3.1 Identified Ongoing Trials; 6.3.2 Identified Published Research; 6.3.3 DOT-HTN Procedures Reported in the Reviewed Literature; 6.4 Discussion; References; 7: Digital Medicines to Measure Drug Ingestion Adherence; 7.1 Introduction; 7.2 Digital Medicines; 7.3 Pre-approval Studies.